Related Experiment Videos
Experimental study using heparin-immobilized adsorbent of EDA(+)fibronectin
M Yonekawa1, M Tanaka, A Kawamura
1Research Institute for Artificial Organs, Transplantation, and Gene Therapy, Sapporo Hokuyu Hospital, Japan.
Summary
A new heparin-based adsorbent effectively removed EDA(+)fibronectin, a protein linked to immune diseases, in rats with experimental arthritis. This targeted approach showed promising therapeutic potential for immune-related conditions.
Area of Science:
- Biomedical Engineering
- Immunology
- Rheumatology
Background:
- EDA(+)fibronectin is implicated in the pathogenesis and progression of immune diseases.
- Current plasma removal methods like cryofiltration are non-specific, removing beneficial proteins alongside target molecules.
- A novel adsorbent utilizing heparin's high affinity for EDA(+)fibronectin was developed for targeted removal.
Purpose of the Study:
- To evaluate the efficacy of a heparin-immobilized adsorbent (OHC-20) for removing EDA(+)fibronectin.
- To assess the therapeutic potential of OHC-20 in a rat model of experimental arthritis.
Main Methods:
- Experimental arthritis was induced in Lewis rats using Mycobacterium butyricum.
- Rats were divided into non-treatment and three treatment groups receiving adsorption therapy on different schedules (Days 1-5, 7-11, 13-17).
- Therapeutic efficacy was assessed by observing walking posture and hind-foot volume changes.
Main Results:
- Adsorption therapy significantly improved walking posture in treated rats, shifting from dragging to tiptoe walking.
- The increase in hind-foot volume, a marker of inflammation, was suppressed in treatment groups B and C.
- OHC-20 demonstrated effective removal of EDA(+)fibronectin, leading to clinical improvements in experimental arthritis.
Conclusions:
- Heparin-immobilized adsorbents show promise as a targeted therapy for immune diseases.
- OHC-20 offers a potential strategy for managing conditions associated with EDA(+)fibronectin.
- Targeted protein adsorption represents a viable therapeutic avenue for immune-related disorders.